FDA Accepts NDA for Longer-Acting Aripiprazole
September 14, 2022
Aripiprazole, currently available as a once-monthly injection under the brand name Abilify Maintena, is being reviewed as a two-month therapy. The FDA target date for completion of the review is April 27, 2023.